Hansa Biopharma AB (publ) (STO: HNSA)
Sweden
· Delayed Price · Currency is SEK 32.10
-1.36 (-4.06%)
Jan 20, 2025, 5:29 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 48.66M SEK in the quarter ending September 30, 2024, with 113.09% growth. This brings the company's revenue in the last twelve months to 189.39M, up 65.48% year-over-year. In the year 2023, Hansa Biopharma AB had annual revenue of 134.09M, down -13.22%.
Revenue (ttm)
189.39M
Revenue Growth
+65.48%
P/S Ratio
10.01
Revenue / Employee
1.40M
Employees
168
Market Cap
2.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
| Dec 31, 2019 | 3.36M | 6.00K | 0.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 25.44B |
| Getinge AB | 33.59B |
| Sectra AB | 3.14B |
| Camurus AB | 1.69B |
| Medicover AB | 22.60B |
| Vitrolife AB | 3.56B |
| Bonesupport Holding AB | 814.46M |
| Elekta AB | 17.72B |
Hansa Biopharma AB News
- 4 weeks ago - Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome - PRNewsWire
- 6 weeks ago - Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease - PRNewsWire
- 7 weeks ago - Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome - Business Wire
- 7 weeks ago - Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome - PRNewsWire
- 2 months ago - Hansa Biopharma to Attend Truist Securities BioPharma Symposium - PRNewsWire
- 3 months ago - Hansa Biopharma AB (publ) (HNSBF) Q3 2024 Results Conference Call Transcript - Seeking Alpha
- 3 months ago - Hansa Biopharma AB (publ) 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results - PRNewsWire